Avoro Calls Merck's $180/sh Offer for Acceleron Pharma (XLRN) Inadequate; Urges Shareholders Not to Tender

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. VKTX
8. PRGS
9. DGX
10. IONQ

Go back to Avoro Calls Merck's $180/sh Offer for Acceleron Pharma (XLRN) Inadequate; Urges Shareholders Not to Tender

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

November 9, 2021 5:31 PM EST

Believes Now Is the Wrong Time to Cash out of Acceleron, Given Companys Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data

Sees Continuing as Standalone Entity as Clearly Superior Path for Acceleron

Highlights What It Believes Was a Flawed and Inadequate Sale Process, Including Not Pursuing Other Strategic Alternatives

Avoro Stands Ready to Support an Independent Acceleron

NEW YORK--(BUSINESS WIRE)-- Avoro Capital Advisors (Avoro), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its... More